Humans ; Lymphoma ; Lymphoma, B-Cell/genetics* ; Lymphoma, Large B-Cell, Diffuse/genetics* ; Mediastinal Neoplasms/genetics* ; Pathology, Molecular

OBJECTIVE: To analyze the relationship between microRNA (miR)-21, miR-191 and clinical stage of patients with diffuse large B-cell lymphoma (DLBCL). METHODS: 100 patients with DLBCL treated in Shanxi Fenyang Hospital from January 2019 to January 2021 were selected as the research subjects. All patients was divided into stage I, stage II, stage III and stage IV according to Ann-Arbor (Cotswolds) staging system at admission. The baseline data of patients at different clinical stages were counted and compared in detail. The relationship between the levels of miR-21 and miR-191 and the clinical stage of DLBCL patients was mainly analyzed. RESULTS: Among the 100 patients with DLBCL, there were 15 patients at stage I, 25 patients at stage II, 37 patients at stage III and 23 patients at stage IV. The levels of miR-21 and miR-191 in patients at stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were increased gradually, which showed statistically significant differences (P<0.05). According to Kendall's tau-b correlation analysis, it was found that the levels of miR-21 and miR-191 were positively correlated with the clinical stage of DLBCL patients (r=0.566, 0.636). Multiple logistic regression analysis showed that the overexpression of serum miR-21 and miR-191 was a risk factor for high clinical stage in patients with DLBCL (OR>1, P<0.05). Bivariate Pearson correlation analysis showed that there was a positive correlation between miR-21 and miR-191 levels in patients with DLBCL (r=0.339). CONCLUSION The overexpression of miR-21 and miR-191 in patients with DLBCL is related to high clinical stage.
Humans ; Prognosis ; Lymphoma, Large B-Cell, Diffuse/genetics* ; MicroRNAs/genetics*

Lymphomas are the most common ones of hematologic tumors. In China, Hodgkin's lymphoma accounts for 9% - 10% of lymphomas, which has a good response to chemotherapy, while non-Hodgkin's lymphoma accounts for nearly 90% of lymphomas, and the incidence of which tends to rise in recent years. At present, it was realized that miRNA and lymphomas are closely related to each other. More attention has been paid to the effects of miRNA on the pathophysiological process of lymphoma. This review is focused on miRNA-155, one of the miRNA family members, and its action mechanism in diffuse large B-cell lymphoma, Burkitt lymphoma and Hodgkin's lymphoma, expecting to shed light on the future therapy.
Animals ; Burkitt Lymphoma ; Hodgkin Disease ; Humans ; Lymphoma ; genetics ; Lymphoma, Large B-Cell, Diffuse ; MicroRNAs

Humans ; Lymphoma ; classification ; genetics ; pathology ; Lymphoma, Follicular ; genetics ; pathology ; Lymphoma, Large B-Cell, Diffuse ; genetics ; pathology ; Lymphoma, Mantle-Cell ; genetics ; pathology ; World Health Organization

OBJECTIVE: To investigate the expression and significance of LncRNA RP11-513G11.1 in peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), and to analyze its correlation with clinicopathological features and prognosis of patients. METHODS: The serum samples of 93 patients with DLBCL(DLBCL group) and 62 normal persons (control group) were collected from the Department of Hematology, Southwest Medical University. The expression of RP11-513G11.1 in serum samples was detected by real-time fluorescence quantitative PCR, the relationship between the RP11-513G11.1 expression with clinicopathological characteristics and prognosis was analyzed. RESULTS: Compared with normal control group, the expression of RP11-513G11.1 significantly increased in DLBCL patients (P<0.001). The expression of RP11-513G11.1 not related with the age, sex, course of treatment and germinal center B-cell-like lymphoma(GCB) subtypes of the patients, but it related with the diameter of tumor,Ann Arbor stage,B symptoms,chemosensitivity and the international prognostic index(IPI) (P<0.05). The progression-free survival time and overall survival time of patients, whom with high expression of RP11-513G11.1 were significantly shorter than those of RP11-513G11.1 low expression（P<0.001）. The median progression-free survival time and overall survival time of chemotherapy-sensitive patients were significantly longer than those of chemotherapy-resistant patients (P<0.001). Univariate analysis and multivariate Cox regression analysis showed that Ann Arbor stage, RP11-513G11.1 expression, IPI and chemosensitivity were also the independent factors affecting the prognosis of DLBCL patients（P<0.05）. CONCLUSION RP11-513G11.1 is highly expressed in patients with DLBCL, which is related with the prognosis of DLBCL patients.
B-Lymphocytes ; Germinal Center ; Humans ; Lymphoma, Large B-Cell, Diffuse ; genetics ; Prognosis ; RNA, Long Noncoding ; genetics

B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic alterations with high heterogeneity. Precise subtypes with distinct genomic and/or gene expression patterns have been recently revealed using high-throughput sequencing technology. Most of these profiles are associated with recurrent non-overlapping rearrangements or hotspot point mutations that are analogous to the established subtypes, such as DUX4 rearrangements, MEF2D rearrangements, ZNF384/ZNF362 rearrangements, NUTM1 rearrangements, BCL2/MYC and/or BCL6 rearrangements, ETV6-RUNX1-like gene expression, PAX5alt (diverse PAX5 alterations, including rearrangements, intragenic amplifications, or mutations), and hotspot mutations PAX5 (p.Pro80Arg) with biallelic PAX5 alterations, IKZF1 (p.Asn159Tyr), and ZEB2 (p.His1038Arg). These molecular subtypes could be classified by gene expression patterns with RNA-seq technology. Refined molecular classification greatly improved the treatment strategy. Multiagent therapy regimens, including target inhibitors (e.g., imatinib), immunomodulators, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, are transforming the clinical practice from chemotherapy drugs to personalized medicine in the field of risk-directed disease management. We provide an update on our knowledge of emerging molecular subtypes and therapeutic targets in BCP-ALL.
B-Lymphocytes ; Humans ; Mutation ; Oncogene Proteins, Fusion/genetics* ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ; Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-cell lymphoma is the most common malignant lymphoma, and its incidence is increasing year by year. Some types are often indistinguishable from the reactive lesions through morphology combined with immunohistochemistry, so other auxiliary diagnostic methods are urgently needed. Since B-cell lymphoma is caused by malignant transformation of IGH rearranged B cells, the molecular characteristics of rearranged B cells can be used as an important reference for differentiating benign and malignant proliferations of lymphatic tissues. With the development of molecular biology technology, the detection of clonal rearrangement of IGH plays an important role in the diagnosis, efficacy evaluation and prognosis evaluation of lymphoma. This paper focuses on the molecular characteristics and clinical significance of clonal rearrangement of IGH in B-cell lymphoma.
Gene Rearrangement ; Humans ; Lymphoid Tissue/pathology* ; Lymphoma ; Lymphoma, B-Cell/genetics* ; Polymerase Chain Reaction

<b>OBJECTIVEb>To explore an efficient way to knockout microRNA genes in hemapoietic cell lines with a very low transfection efficiency, so as to facilitate the study of microRNA function in hematopoietic malignancies.

<b>METHODSb>TALE-nucleases was utilized to knockout the microRNA-21 gene in human diffuse large B-cell lymphoma cells (OCI-Ly3). The OCI-Ly3 single cell clones without expression of miR-21 were established through eGFP(+) enrichment, PCR screening, and microRNA quantification. Finally, the miR-21 changes of mutant clones were identified by sequencing.

<b>RESULTSb>Four miR-21-knockouted OCI-Ly3 single-cell-derived clones were established after 2 round transfection and screening. The miR-21 knockout efficiency was around 10/10(6) original cells. Sequencing the mutant clones indicated that miR-21 expression could be drastically reduced by simply altering sequences immediately adjacent to the microRNA duplex.

<b>CONCLUSIONb>This strategy may be applied to knockout any microRNA of interest even in hemapoietic cell lines with very low transfection efficiency.

Humans ; Lymphoma, B-Cell, Marginal Zone ; genetics ; pathology ; Splenic Neoplasms ; genetics ; pathology

OBJECTIVE: RAG1 plays important roles in lymphopoiesis and immune system, its dysfunction may result in the malignancies of hemopoietic system. The aim of this study was to investigate the characteristics of RAG1 expression in adult B-cell acute lymphoblastic leukemia (B-ALL), and to analyze the clinical significances. METHODS: Quantitative PCR (q-PCR) was performed to evaluate the expression of RAG1 in 104 newly diagnosed, 22 relapsed adult B-ALL patients and 30 normal controls, the clinical significances of RAG1 expression were analyzed. RESULTS: Compared with normal controls, newly diagnosed and relapsed adult B-ALL patients showed higher RAG1 expression level (3.94 vs 1.23) (P＜0.01), (5.86 vs 1.23) (P＜0.01). The analysis of paired simples from 6 cases of newly diagnosed and relapsed B-ALL showed that the expression level of RAG1 at relapse was significantly higher than that at new diagnosis (13.65 vs 2.31) (P＜0.01). The RAG1 expression level in IK6 positive patients was higher than that in IK6 negative patients (5.30 vs 2.11) (P＜0.05). The ratio of patients with LDH＞1 000 U/L in RAG1 high expression group was higher than that in RAG1 low expression group (42.2% vs 20.5%) (P＜0.05). CONCLUSION RAG1 up-regulation may play an important role in the development of adult B-ALL especially when relapsed, which may also take part in the formation of Ik6. Monitoring RAG1 expression may provide a new method to evaluate the prognosis of adult B-ALL patients.
Acute Disease ; Adult ; B-Lymphocytes ; Homeodomain Proteins ; genetics ; Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; genetics ; Prognosis